BOSTON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported second quarter 2025 financial results and provided a business update on its clinical and pre-clinical programs.
Related Questions
How will the reported Q2 2025 financial results affect CMPX's short-term stock price momentum?
What specific clinical and pre‑clinical program updates were disclosed, and how might they impact future revenue forecasts?
How does Compass Therapeutics' Q2 performance compare to consensus analyst expectations and to peers in the oncology biopharma space?
Are there any changes to the company's cash runway or capital allocation strategy that could influence valuation?
What regulatory milestones or trial readouts are expected in the near term, and how could they drive market sentiment?
Did the company provide guidance for Q3 2025 or the full‑year 2025, and how reliable is that guidance given historical performance?
What potential partnership, licensing, or acquisition activities were hinted at in the corporate update?
How might the disclosed results affect the risk/reward profile for existing and prospective investors in CMPX?